Published in Cancer Res on November 15, 2005
Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res (2009) 5.20
Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer (2009) 4.66
Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov (2009) 4.16
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene (2007) 3.17
ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci U S A (2007) 2.85
Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol (2009) 2.50
The requirement for cyclin D function in tumor maintenance. Cancer Cell (2012) 2.49
Therapeutic strategies for targeting ras proteins. Genes Cancer (2011) 2.45
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst (2012) 1.81
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell (2013) 1.37
Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle (2011) 1.27
The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2. Oncogene (2010) 1.15
Cdk2 and Cdk4 regulate the centrosome cycle and are critical mediators of centrosome amplification in p53-null cells. Mol Cell Biol (2009) 1.12
CDK4: A Key Player in the Cell Cycle, Development, and Cancer. Genes Cancer (2012) 1.07
The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Res (2013) 1.06
Heterogeneity of mammary lesions represent molecular differences. BMC Cancer (2006) 0.98
Cyclin-dependent kinase 3-mediated activating transcription factor 1 phosphorylation enhances cell transformation. Cancer Res (2008) 0.97
p19Ink4d is a tumor suppressor and controls pituitary anterior lobe cell proliferation. Mol Cell Biol (2014) 0.97
The G1 phase Cdks regulate the centrosome cycle and mediate oncogene-dependent centrosome amplification. Cell Div (2011) 0.90
Cyclins and cell cycle control in cancer and disease. Genes Cancer (2012) 0.90
Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity. Cell Cycle (2013) 0.89
D-type Cyclins are important downstream effectors of cytokine signaling that regulate the proliferation of normal and neoplastic mammary epithelial cells. Mol Cell Endocrinol (2013) 0.89
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res (2016) 0.87
Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. PLoS One (2010) 0.87
Cdk4 and nek2 signal binucleation and centrosome amplification in a her2+ breast cancer model. PLoS One (2013) 0.86
Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesis. Neoplasia (2011) 0.86
Assembly, activation, and substrate specificity of cyclin D1/Cdk2 complexes. Biochemistry (2013) 0.83
The Role of CDK4/6 Inhibition in Breast Cancer. Oncologist (2015) 0.83
Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis. Cell Div (2013) 0.83
HER-2/neu x aromatase double transgenic mice model: the effects of aromatase overexpression on mammary tumorigenesis. J Steroid Biochem Mol Biol (2007) 0.82
RelA-Induced Interferon Response Negatively Regulates Proliferation. PLoS One (2015) 0.81
CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene (2015) 0.81
Requirement of Cdk4 for v-Ha-ras-Induced Breast Tumorigenesis and Activation of the v-ras-Induced Senescence Program by the R24C Mutation. Genes Cancer (2010) 0.81
Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer (2017) 0.81
Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics. Mol Pharmacol (2015) 0.75
Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Ther Adv Med Oncol (2016) 0.75
Kip3-ing kinetochores clustered. Cell Cycle (2010) 0.75
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell (2005) 3.56
Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling. Cell Metab (2011) 2.73
Characterization of the abnormal pancreatic development, reduced growth and infertility in Cdk4 mutant mice. Oncogene (2003) 2.64
Cellular control of gene expression by T-type cyclin/CDK9 complexes. Gene (2004) 1.73
Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol Cell Biol (2002) 1.58
JAKs, STATs and Src kinases in hematopoiesis. Oncogene (2002) 1.56
Activation of p38alpha/beta MAPK in myogenesis via binding of the scaffold protein JLP to the cell surface protein Cdo. J Cell Biol (2006) 1.52
Transforming growth factor-beta/Smad3 signaling regulates insulin gene transcription and pancreatic islet beta-cell function. J Biol Chem (2009) 1.49
Conditional c-myb knockout in adult hematopoietic stem cells leads to loss of self-renewal due to impaired proliferation and accelerated differentiation. Proc Natl Acad Sci U S A (2009) 1.48
The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci (2013) 1.42
CDK9 is constitutively expressed throughout the cell cycle, and its steady-state expression is independent of SKP2. Mol Cell Biol (2003) 1.42
Increased angiogenesis in Cdk4(R24C/R24C):Apc(+/Min) intestinal tumors. Cell Cycle (2010) 1.40
Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis. Cancer Res (2005) 1.37
Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer (2010) 1.34
Requirement of c-myb in T cell development and in mature T cell function. Proc Natl Acad Sci U S A (2004) 1.32
Cdk4 promotes adipogenesis through PPARgamma activation. Cell Metab (2005) 1.31
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci U S A (2005) 1.30
Nucleocytoplasmic shuttling of the retinoblastoma tumor suppressor protein via Cdk phosphorylation-dependent nuclear export. J Biol Chem (2006) 1.28
Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology (2010) 1.26
Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem (2013) 1.25
JLP: A scaffolding protein that tethers JNK/p38MAPK signaling modules and transcription factors. Proc Natl Acad Sci U S A (2002) 1.22
SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells. Oncogene (2003) 1.17
Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases. Int J Cancer (2010) 1.16
Cyclin T1 expression is regulated by multiple signaling pathways and mechanisms during activation of human peripheral blood lymphocytes. J Immunol (2005) 1.08
Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation. Cancer Res (2011) 1.08
CDK4: A Key Player in the Cell Cycle, Development, and Cancer. Genes Cancer (2012) 1.07
Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes. Gene (2007) 1.07
CXCR3 surface expression in human airway epithelial cells: cell cycle dependence and effect on cell proliferation. Am J Physiol Lung Cell Mol Physiol (2005) 1.06
Selective control of gene expression by CDK9 in human cells. J Cell Physiol (2010) 1.06
Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML). Genes Cancer (2010) 1.05
Periostin-like-factor in osteogenesis. J Cell Physiol (2009) 1.05
Molecular mechanisms associated with the regulation of apoptosis by the two alternatively spliced products of c-Myb. Mol Cell Biol (2003) 1.03
JLP associates with kinesin light chain 1 through a novel leucine zipper-like domain. J Biol Chem (2005) 1.03
The chemokine receptor CXCR3 and its splice variant are expressed in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol (2004) 1.02
Exposure-dependent increases in IL-1beta, substance P, CTGF, and tendinosis in flexor digitorum tendons with upper extremity repetitive strain injury. J Orthop Res (2010) 0.98
Periostin-like-factor and Periostin in an animal model of work-related musculoskeletal disorder. Bone (2008) 0.98
Design, synthesis, and biological evaluation of (E)-styrylbenzylsulfones as novel anticancer agents. J Med Chem (2007) 0.98
Design, synthesis and evaluation of (E)-alpha-benzylthio chalcones as novel inhibitors of BCR-ABL kinase. Bioorg Med Chem (2010) 0.97
An in vivo functional screen uncovers miR-150-mediated regulation of hematopoietic injury response. Cell Rep (2012) 0.97
Cyclin E and SV40 small T antigen cooperate to bypass quiescence and contribute to transformation by activating CDK2 in human fibroblasts. J Biol Chem (2008) 0.96
PP2A holoenzymes negatively and positively regulate cell cycle progression by dephosphorylating pocket proteins and multiple CDK substrates. Gene (2012) 0.96
A dynamic equilibrium between CDKs and PP2A modulates phosphorylation of pRB, p107 and p130. Cell Cycle (2004) 0.95
Transforming growth factor-β adaptor, β2-spectrin, modulates cyclin dependent kinase 4 to reduce development of hepatocellular cancer. Hepatology (2011) 0.95
Epigenetic silencing of beta-spectrin, a TGF-beta signaling/scaffolding protein in a human cancer stem cell disorder: Beckwith-Wiedemann syndrome. J Biol Chem (2010) 0.95
Immunolocalization of Periostin-like factor and Periostin during embryogenesis. J Histochem Cytochem (2007) 0.94
RB regulates pancreas development by stabilizing Pdx1. EMBO J (2011) 0.93
TGF-β/Smad3 Signaling Regulates Brown Adipocyte Induction in White Adipose Tissue. Front Endocrinol (Lausanne) (2012) 0.92
Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms. Radiat Res (2009) 0.92
A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans. Gastroenterology (2012) 0.92
Induction of periostin-like factor and periostin in forearm muscle, tendon, and nerve in an animal model of work-related musculoskeletal disorder. J Histochem Cytochem (2009) 0.91
The Cdk4-E2f1 pathway regulates early pancreas development by targeting Pdx1+ progenitors and Ngn3+ endocrine precursors. Development (2011) 0.90
B55alpha PP2A holoenzymes modulate the phosphorylation status of the retinoblastoma-related protein p107 and its activation. J Biol Chem (2010) 0.90
Cdk4 regulates recruitment of quiescent beta-cells and ductal epithelial progenitors to reconstitute beta-cell mass. PLoS One (2010) 0.90
Myb permits multilineage airway epithelial cell differentiation. Stem Cells (2014) 0.90
Complex effects of flavopiridol on the expression of primary response genes. Cell Div (2012) 0.88
JNK-interacting leucine zipper protein is a novel scaffolding protein in the Galpha13 signaling pathway. Biochemistry (2005) 0.88
PP2A Counterbalances Phosphorylation of pRB and Mitotic Proteins by Multiple CDKs: Potential Implications for PP2A Disruption in Cancer. Genes Cancer (2012) 0.87
Regulation of neurite outgrowth by interactions between the scaffolding protein, JNK-associated leucine zipper protein, and neuronal growth-associated protein superior cervical ganglia clone 10. J Biol Chem (2009) 0.87
Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors. Bioorg Med Chem (2008) 0.87
Coordinated activation of the origin licensing factor CDC6 and CDK2 in resting human fibroblasts expressing SV40 small T antigen and cyclin E. J Biol Chem (2009) 0.86
Transforming pathways activated by the v-Abl tyrosine kinase. Oncogene (2002) 0.86
Novel coumarin-3-(N-aryl)carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1. Bioorg Med Chem (2005) 0.85
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. Genes Cancer (2010) 0.85
Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. Blood (2004) 0.85
Endodermal differentiation of murine embryonic carcinoma cells by retinoic acid requires JLP, a JNK-scaffolding protein. J Cell Biochem (2006) 0.84
Characterization of cardiac muscle factor 1 sequence motifs: retinoblastoma protein binding and nuclear localization. Gene (2002) 0.84
Performance of repetitive tasks induces decreased grip strength and increased fibrogenic proteins in skeletal muscle: role of force and inflammation. PLoS One (2012) 0.84
Neoplastic transformation induced by the gep oncogenes involves the scaffold protein JNK-interacting leucine zipper protein. Neoplasia (2011) 0.84
Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity. Bioorg Med Chem Lett (2004) 0.83
B-myb is an essential regulator of hematopoietic stem cell and myeloid progenitor cell development. Proc Natl Acad Sci U S A (2014) 0.83
Activation of p107 by fibroblast growth factor, which is essential for chondrocyte cell cycle exit, is mediated by the protein phosphatase 2A/B55α holoenzyme. Mol Cell Biol (2013) 0.82
Targeted inhibition of kinases in cancer therapy. Mt Sinai J Med (2010) 0.82
Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy. AAPS J (2012) 0.82
Transforming growth factor-β3 (TGF-β3) knock-in ameliorates inflammation due to TGF-β1 deficiency while promoting glucose tolerance. J Biol Chem (2013) 0.81
E2F-dependent repression of topoisomerase II regulates heterochromatin formation and apoptosis in cells with melanoma-prone mutation. Cancer Res (2005) 0.81
Mechanisms associated with IL-6-induced up-regulation of Jak3 and its role in monocytic differentiation. Blood (2004) 0.81
Requirement of Cdk4 for v-Ha-ras-Induced Breast Tumorigenesis and Activation of the v-ras-Induced Senescence Program by the R24C Mutation. Genes Cancer (2010) 0.81
PP2A: more than a reset switch to activate pRB proteins during the cell cycle and in response to signaling cues. Cell Cycle (2015) 0.81
Impaired adult myeloid progenitor CMP and GMP cell function in conditional c-myb-knockout mice. Cell Cycle (2012) 0.81
Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models. Mol Cancer Ther (2014) 0.80
c-Myc is essential but not sufficient for c-Myb-mediated block of granulocytic differentiation. J Biol Chem (2003) 0.80
Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy. Pharm Res (2012) 0.79
Cooperativity of Cdk4R24C and Ras in melanoma development. Cell Cycle (2010) 0.79
Activation of the Jak3 pathway is associated with granulocytic differentiation of myeloid precursor cells. Blood (2002) 0.79
p21 loss cooperates with INK4 inactivation facilitating immortalization and Bcl-2-mediated anchorage-independent growth of oncogene-transduced primary mouse fibroblasts. Cancer Res (2007) 0.79
Activation of the Jak3 pathway and myeloid differentiation. Leuk Lymphoma (2005) 0.78
Development of a new ELISA for serum periostin: evaluation of growth-related changes and bisphosphonate treatment in mice. Calcif Tissue Int (2010) 0.78
Combined administration of rituximab and on 013105 induces apoptosis in mantle cell lymphoma cells and reduces tumor burden in a mouse model of mantle cell lymphoma. Clin Cancer Res (2012) 0.77
SMAD3 negatively regulates serum irisin and skeletal muscle FNDC5 and peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) during exercise. J Biol Chem (2015) 0.77
Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents. J Med Chem (2013) 0.77
Hydrothiolation of benzyl mercaptan to arylacetylene: application to the synthesis of (E) and (Z)-isomers of ON 01910·Na (Rigosertib®), a phase III clinical stage anti-cancer agent. Org Biomol Chem (2013) 0.77